Envista (NVST) Q4 2024 earnings summary

Executive summary

• Q4 2024 results met expectations with 2% core sales growth and a 13.9% adjusted EBITDA margin, supported by operational improvements and a refreshed leadership team.

• Spark aligners and implants showed continued growth and share gains, especially in North America.

• FY24 free cash flow reached $303 million, up 35% year-over-year, supporting a $250 million share repurchase authorization.

• Full-year 2024 net loss was $1.12 billion, mainly due to $1.15 billion in goodwill and intangible asset impairments.

• Dental market remains soft but stable, with headwinds in China and diagnostics.

Financial highlights

• Q4 2024 sales were $653 million, with core sales up 2% year-over-year after adjusting for FX.

• Adjusted gross margin in Q4 was 57.2%, up nearly 500 bps year-over-year.

• Adjusted EBITDA margin for Q4 was 13.9%, down from 15.6% in Q4 2023.

• Adjusted EPS for Q4 was $0.24, down from $0.29 in Q4 2023.

• Q4 free cash flow was $123.9 million; full-year free cash flow reached $303 million.

Outlook and guidance

• 2025 guidance: 1%-3% core growth, ~14% adjusted EBITDA margin, and EPS of $0.95-$1.05, assuming a stable dental market.

• FX rates assumed flat; strong USD is a 2% revenue headwind.

• Restructuring expected to yield ~$20 million in annualized savings, mostly benefiting 2025.

• Share repurchase authorization of $250 million through 2026.

• Anticipates slower growth in H1 2025, with improvement in H2 as China and Spark headwinds ease.